Slashdot Mirror

An anonymous reader shares a report: In Idaho, Nebraska, and Utah, voters will directly decide whether their states should expand their Medicaid programs. In Wisconsin, they could elect a candidate for governor who has pledged to sharply curtail drug prices. And across the country, Democratic congressional candidates are running on platforms highlighting their support for protecting insurance coverage for those with pre-existing conditions and lowering drug prices. Health care is on the ballot across the country, with issues ranging from medical marijuana to abortion rights to insurance coverage dominating the conversation.

An anonymous reader quotes a report from Gizmodo: Internal company documents from IBM show that medical experts working with the company's Watson supercomputer found "multiple examples of unsafe and incorrect treatment recommendations" when using the software, according to a report from Stat News. According to Stat, those documents provided strong criticism of the Watson for Oncology system, and stated that the "often inaccurate" suggestions made by the product bring up "serious questions about the process for building content and the underlying technology." One example in the documents is the case of a 65-year-old man diagnosed with lung cancer, who also seemed to have severe bleeding. Watson reportedly suggested the man be administered both chemotherapy and the drug "Bevacizumab." But the drug can lead to "severe or fatal hemorrhage," according to a warning on the medication, and therefore shouldn't be given to people with severe bleeding, as Stat points out. A Memorial Sloan Kettering (MSK) Cancer Center spokesperson told Stat that they believed this recommendation was not given to a real patient, and was just a part of system testing.

According to the report, the documents blame the training provided by IBM engineers and on doctors at MSK, which partnered with IBM in 2012 to train Watson to "think" more like a doctor. The documents state that -- instead of feeding real patient data into the software -- the doctors were reportedly feeding Watson hypothetical patients data, or "synthetic" case data. This would mean it's possible that when other hospitals used the MSK-trained Watson for Oncology, doctors were receiving treatment recommendations guided by MSK doctors' treatment preferences, instead of an AI interpretation of actual patient data. And the results seem to be less than desirable for some doctors.

The U.S. Food and Drug Administration on Monday approved the first prescription drug derived from the marijuana plant, as a treatment for rare forms of epilepsy that primarily afflict children. From a report: The FDA said Monday that it cleared GW Pharmaceuticals's Epidiolex, also known as cannabidiol, to reduce seizures associated with forms of epilepsy known as Lennox-Gastaut syndrome and Dravet syndrome, in patients 2 years of age and older. Cannabidiol is derived from the cannabis plant, also known as marijuana. U.K.-based GW Pharmaceuticals says the solution, taken by mouth, is made from a proprietary strain of cannabis designed to maximize a therapeutic component while minimizing components that produce euphoria. GW Pharmaceuticals grows the plants in the U.K.

The FDA said Monday that the drug doesn't cause the high that comes from the chemical tetrahydrocannabinol, or THC, which is the main psychoactive component of marijuana. FDA officials also said the drug doesn't appear to have abuse potential, citing minimal reports of euphoria in patients who took the drug in clinical studies. Further reading: StatNews, The Guardian, and FDA.

Editing cell genomes with CRISPR-Cas9 might increase the risk of developing cancer, two studies published Monday warn. From a report: Editing cells' genomes with CRISPR-Cas9 might increase the risk that the altered cells, intended to treat disease, will trigger cancer, two studies published on Monday warn -- a potential game-changer for the companies developing CRISPR-based therapies. In the studies, published in Nature Medicine, scientists found that cells whose genomes are successfully edited by CRISPR-Cas9 have the potential to seed tumors inside a patient. That could make some CRISPR'd cells ticking time bombs, according to researchers from Sweden's Karolinska Institute and, separately, Novartis. CRISPR has already dodged two potentially fatal bullets -- a 2017 claim that it causes sky-high numbers of off-target effects was retracted in March, and a report of human immunity to Cas9 was largely shrugged off as solvable. But experts are taking the cancer-risk finding seriously.

"Nightmare bacteria" with unusual resistance to antibiotics of last resort were found more than 200 times in the United States last year in a first-of-a-kind hunt to see how much of a threat these rare cases are becoming, health officials said this week. From a report: That's more than they had expected to find, and the true number is probably higher because the effort involved only certain labs in each state, officials say. The problem mostly strikes people in hospitals and nursing homes who need IVs and other tubes that can get infected. In many cases, others in close contact with these patients also harbored the superbugs even though they weren't sick -- a risk for further spread. Some of the sick patients had traveled for surgery or other health care to another country where drug-resistant germs are more common, and the superbug infections were discovered after they returned to the U.S.

DNA testing won't guide dieters to the weight-loss regimen most likely to work for them, scientists reported on Tuesday. From a report: Despite some earlier studies claiming that genetic variants predict whether someone has a better chance of shedding pounds on a low-carbohydrate or a low-fat diet, and despite a growing industry premised on that notion, the most rigorous study so far found no difference in weight loss between overweight people on diets that "matched" their genotype and those on diets that didn't. The findings make it less likely that genetics might explain why only some people manage to lose weight on a low-carb diet like Atkins and why others succeed with a low-fat one (even though the vast majority of dieters don't keep off whatever pounds they lose). Unlike cancer treatments, diets can't be matched to genotype, the new study shows. The results underline "how, for most people, knowing genetic risk information doesn't have a big impact," said Timothy Caulfield, of the University of Alberta, a critic of quackery.

U.S. regulators have approved the first drug aimed at women with advanced breast cancer caused by an inherited flawed gene. From a report: The Food and Drug Administration on Friday approved AstraZeneca PLC's Lynparza for patients with inherited BRCA gene mutations who have undergone chemotherapy. The drug has been on the market since 2014 for ovarian cancer, and is the first in a new class of medicines called PARP inhibitors to be approved for breast cancer. PARP inhibitors prevent cancer cells from fixing problems in their DNA. Lynparza will cost $13,886 per month without insurance, according to AstraZeneca. The company is offering patients financial assistance.

At the annual meeting of the Society for Neuroscience starting November 11 in Washington D.C., two teams of scientists plan to present previously unpublished research on the unexpected interaction between human mini-brains and their rat and mouse hosts. "In the new papers, according to STAT, scientists will report that the organoids survived for extended periods of time -- two months in one case -- and even connected to lab animals' circulatory and nervous systems, transferring blood and nerve signals between the host animal and the implanted human cells," reports Inverse. "This is an unprecedented advancement for mini-brain research." From the report: That mini-brains can even be grown in the lab is a huge advancement in the first place, as they have many of the same characteristics as living human brains that are in the early stages of development. Though they're not "alive" in the same sense that you and I are, they grow and are organized into different layers like our brains are. They even react in similar ways to stimuli like psychedelic drugs. Organoids are poised to revolutionize research on the human brain since scientists can perform tests on them that would be unethical to attempt on living humans. STAT also reports that a third lab, in addition to the two presenting at the Society for Neuroscience meeting, has successfully connected human brain organoids to blood vessels. This attempt veered into such challenging ethical territory, though, that the lab reportedly paused its efforts.

IBM began selling Watson to recommend the best cancer treatments to doctors around the world three years ago. But is it really doing its job? Not so much. An investigation by Stat found that the supercomputer isn't living up to the lofty expectations IBM created for it. It is still struggling with the basic step of learning about different forms of cancer. Only a few dozen hospitals have adopted the system, which is a long way from IBM's goal of establishing dominance in a multibillion-dollar market. And at foreign hospitals, physicians complained its advice is biased toward American patients and methods of care. From the report: The interviews suggest that IBM, in its rush to bolster flagging revenue, unleashed a product without fully assessing the challenges of deploying it in hospitals globally. While it has emphatically marketed Watson for cancer care, IBM hasn't published any scientific papers demonstrating how the technology affects physicians and patients. As a result, its flaws are getting exposed on the front lines of care by doctors and researchers who say that the system, while promising in some respects, remains undeveloped. [...] Perhaps the most stunning overreach is in the company's claim that Watson for Oncology, through artificial intelligence, can sift through reams of data to generate new insights and identify, as an IBM sales rep put it, "even new approaches" to cancer care. STAT found that the system doesn't create new knowledge and is artificially intelligent only in the most rudimentary sense of the term.

Tom Randall, reporting for Bloomberg Technology:An experimental cancer treatment that alters the DNA of patients has won a key approval to proceed with its first human tests using the controversial gene-altering tool known as Crispr. Scientists from the University of Pennsylvania want to edit the immune systems of 18 patients to target cancer cells more effectively. The experiment, backed by internet billionaire Sean Parker, won approval from the Recombinant DNA Advisory Committee (RAC), a federal ethics panel set up at the National Institutes of Health 40 years ago to review controversial experiments that change the human genome. The trial still needs final approval from the U.S. Food and Drug Administration. The experiment targets difficult-to-treat cases of multiple myeloma, sarcoma, and melanoma. The scientists will remove blood samples from patients and alter their T-cells -- central to human immune response -- to more effectively target and pursue cancer. The T cells will then be infused back into patients and studied for the safety and effectiveness of the technique.STAT News has an article in which it discusses the probable consequences of altering the DNA of a cancer patient.

An anonymous reader writes: According to a new study published in the Lancet, obese people now outnumber the underweight population for perhaps the first time in global history. Majid Ezzati, an environmental health researcher at Imperial College London who led the study, analyzed data from 1975 to 2014 across 19.2 million adults from 186 countries. They found that over the 40-year-span, the proportion of obese men worldwide more than tripled, to roughly 11 percent, and the proportion of obese woman more than doubled, to about 15 percent. Researchers estimate 18 percent of men and 21 percent of women worldwide will be obese by 2025. What some may consider more surprising is that more than 25 percent of the world's severely obese men and almost 20 percent of the world's severely obese women are American. However, the rapid rise of obesity in developing nations is most concerning as it's more difficult for obese people to modify their diet and have access to medication.